Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1441 to 1455 of 7691 results

  1. Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (TA261)

    Evidence-based recommendations on rivaroxaban (Xarelto) for treating deep vein thrombosis and preventing a pulmonary embolism or another deep vein thrombosis in adults.

  2. Drug-eluting stents for the treatment of coronary artery disease (TA152)

    Evidence-based recommendations on using drug-eluting stents in adults.

  3. Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (TA161)

    Evidence-based recommendations on raloxifene and teriparatide for preventing osteoporotic fragility fractures in postmenopausal women who have osteoporosis.

  4. Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women (TA160)

    Evidence-based recommendations on raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women.

  5. Rituximab for the first-line treatment of stage III-IV follicular lymphoma (TA243)

    Evidence-based recommendations on rituximab for treating follicular lymphoma in adults.

  6. Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults (TA245)

    Evidence-based recommendations on apixaban (Eliquis) for preventing venous thromboembolism after total hip or knee replacement in adults.

  7. Dapagliflozin in combination therapy for treating type 2 diabetes (TA288)

    Evidence-based recommendations on dapagliflozin (Forxiga) given with other drugs for treating type 2 diabetes in adults.

  8. Nintedanib for treating idiopathic pulmonary fibrosis (TA379)

    Evidence-based recommendations on nintedanib (Ofev) for adults with idiopathic pulmonary fibrosis.

  9. Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma (TA137)

    Evidence-based recommendations on rituximab for treating relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma in adults.

  10. Inhaled corticosteroids for the treatment of chronic asthma in adults and in children aged 12 years and over (TA138)

    Evidence-based recommendations on inhaled corticosteroids for treating chronic asthma in adults and children aged 12 and over.

  11. Carmustine implants for the treatment of recurrent glioblastoma multiforme (terminated appraisal) (TA149)

    NICE is unable to recommend the use in the NHS of carmustine implants as an adjunct to surgery in patients with recurrent glioblastoma multiforme for whom surgical resection is indicated because no evidence submission was received from the manufacturer or sponsor of the technology. We will review this decision if the company decides to make a submission

    Sections for TA149

  12. Structural neuroimaging in first-episode psychosis (TA136)

    Evidence-based recommendations on structural neuroimaging in people with first-episode psychosis.

  13. Pemetrexed for the treatment of malignant pleural mesothelioma (TA135)

    Evidence-based recommendations on pemetrexed for treating malignant pleural mesothelioma in adults.

  14. Varenicline for smoking cessation (TA123)

    Evidence-based recommendations on varenicline (Champix) for adults who want to stop smoking.

  15. Pemetrexed for the treatment of non-small-cell lung cancer (TA124)

    Evidence-based recommendations on pemetrexed for treating non-small-cell lung cancer in adults.